More Than 250,000 BPH Patients Treated with The UroLift® System

On March 9, 2021, Teleflex Incorporated announced that, globally, 250,000* patients have been treated with the UroLift® System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH) that is included in the AUA guidelines.


024 250000 Patients Logo

On March 9, 2021, Teleflex Incorporated announced that, globally, 250,000* patients have been treated with the UroLift® System, a proven, minimally invasive approach to treating benign prostatic hyperplasia (BPH) that is included in the AUA guidelines. 

“The UroLift System is a standard of care in my practice, and I confidently recommend it to appropriate patients who face the challenge of an enlarging prostate,” said Wayne Kuang, M.D.a “Many men are looking for alternatives to medications and major surgeries that have unwanted side effects and risks. The UroLift System may enable men to experience rapid symptom relief, recover from the procedure quickly, and return to their normal routines with minimal downtime.1,2 This minimally invasive procedure can achieve consistent results in a broad range of BPH patients with various anatomies and a wide range of prostate sizes.”

“Celebrating 250,000 patients treated with the UroLift System is an exciting milestone. We thank the physicians in our community who recommend the UroLift System to their patients,” said Jay White, President of the Teleflex Interventional Urology business unit. “Recent clinical data show the UroLift System provides a superior patient experience with better sexual function, lower catheterization rates, less interference with daily activities, and higher patient satisfaction in the early recovery period.b,3 Patients treated with the UroLift System may also achieve better outcomes in sexual function and satisfaction than men who receive medical therapy.c,4 These positive UroLift System outcomes align with our goal at Teleflex to improve the health and quality of patients’ lives.”

 

*Management estimate based on product sales and average units per procedure
 
a  Dr. Wayne Kuang is a paid consultant of NeoTract | Teleflex Interventional Urology. b  Nonrandomized controlled study comparing the early patient experience following treatment with the UroLift System and Rezum™ steam injection. c  Non-head-to-head comparative study examining erectile and ejaculatory function and sexual satisfaction following treatment with the UroLift System or once-daily medical therapy from the MTOPS trial.

1. Roehrborn, J Urology 2013
2. Shore, Can J Urol 2014
3. Tutrone, Can J Urol 2020
4. Roehrborn and Rukstalis. Eur Urol Focus 2020

 

MAC01921-02 Rev A